Publications: 1 monography on Lung Cancer as first author, 12 chapters in co-autorship
161 publications, 56 as first author and 105 as co-author, 71 abroad and 90 in Romania, 77 in extenso and 84 as abstracts.
Member of Professional Societies:
The Romanian Society of Radiotherapy and Oncology, Cluj-Napoca, Romania, 1993 – present (President of the Romanian Society of Radiotherapy and Medical Oncology, 2002-2003)
The Romanian Society Against Cancer, Cluj-Napoca, 1993 – present
The Romanian National Society of Medical Oncology, Craiova, 2000 –present
The American Society of Clinical Oncology, 1999 –present
Certified Member of the European Society of Medical Oncology, 1998 –present
The Central European Cooperative Oncology Group, Wien, Austria, 1998 –present
The Balkan Union of Oncology, Athens, Greece, 1996 – present
(Romanian National Representative in BUON 2000 - present)
The French Cancer Society, Paris, France, 1992 – present
Member of Official Organisations:
Member of the Scientific Council of the Romanian National Drug Agency (1998-2003)
Expert of the Romanina National Drug Agency in relation with EMEA (2007-present)
Member of the Oncology Comission of the National Health Insurance Agency (2006-present)
Member of the National Comission of Oncology of the Romanian Ministry of Public Health (2007-present)
Invited speaker at International and National Symposia, Conferences and Courses.
Investigator in 66 clinical trials.
Selected publications:
Erlotinib in previously treated non-small-cell lung cancer. Shepherd, FA, Pereira, JR, Ciuleanu, T, Tan, EH, Hirsh, V, Thongprasert, S, Campos, D, Maoleekoonpiroj, S, Smylie, M, Martins, R, van Kooten, M, Dediu, M, Findlay, B, Tu, DS, Johnston, D, Bezjak, A, Clark, G, Santabarbara, P, Seymour, L. NEW ENGLAND JOURNAL OF MEDICINE, 353 (2): 123-132, 2005.
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Thatcher, N, Chang, A, Parikh, P, Pereira, JR, Ciuleanu, T, von Pawel, J, Thongprasert, S, Tan, EH, Pemberton, K, Archer, V, Carroll, K. LANCET, 366 (9496): 1527-1537, 2005.
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, LUNG CANCER, 52(2): 155-163. 2006.
Phase III Trial Comparing Supportive Care Alone with Supportive Care with Oral Topotecan in Patients with Relapsed Small-cell Lung Cancer. O’Brien MER, Ciuleanu T-E, Tsekov H et al. JOURNAL OF CLINICAL ONCOLOGY, 24:5441-5447, 2006;
A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer Grigorescu A, Ciuleanu T, Firoiu E, Muresan DR, Teodorescu G, Basson BR. LUNG CANCER, 57, 168-174, 2007
|